- Home
- LFMD vs IMMP Comparison
LFMD vs IMMP Comparison
Compare LFMD & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFMD
- IMMP
- Stock Information
- Founded
- LFMD 1994
- IMMP 1987
- Country
- LFMD United States
- IMMP Australia
- Employees
- LFMD N/A
- IMMP N/A
- Industry
- LFMD Medical/Nursing Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- LFMD Health Care
- IMMP Health Care
- Exchange
- LFMD Nasdaq
- IMMP Nasdaq
- Market Cap
- LFMD 306.7M
- IMMP 304.0M
- IPO Year
- LFMD N/A
- IMMP N/A
- Fundamental
- Price
- LFMD $5.65
- IMMP $1.94
- Analyst Decision
- LFMD Strong Buy
- IMMP Buy
- Analyst Count
- LFMD 7
- IMMP 2
- Target Price
- LFMD $11.57
- IMMP $8.50
- AVG Volume (30 Days)
- LFMD 2.0M
- IMMP 72.7K
- Earning Date
- LFMD 03-10-2025
- IMMP 03-25-2025
- Dividend Yield
- LFMD N/A
- IMMP N/A
- EPS Growth
- LFMD N/A
- IMMP N/A
- EPS
- LFMD N/A
- IMMP N/A
- Revenue
- LFMD $212,453,838.00
- IMMP $3,019,249.00
- Revenue This Year
- LFMD $23.50
- IMMP N/A
- Revenue Next Year
- LFMD $17.20
- IMMP $20.28
- P/E Ratio
- LFMD N/A
- IMMP N/A
- Revenue Growth
- LFMD 39.27
- IMMP 24.11
- 52 Week Low
- LFMD $3.99
- IMMP $1.65
- 52 Week High
- LFMD $12.88
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- LFMD 52.05
- IMMP 52.77
- Support Level
- LFMD $5.47
- IMMP $1.65
- Resistance Level
- LFMD $5.83
- IMMP $1.88
- Average True Range (ATR)
- LFMD 0.51
- IMMP 0.09
- MACD
- LFMD 0.08
- IMMP 0.02
- Stochastic Oscillator
- LFMD 69.62
- IMMP 75.00
About LFMD LifeMD Inc.
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.